Abivax (ABVX) to Release Earnings on Monday

Abivax (NASDAQ:ABVX) is anticipated to post its Q2 2025 quarterly earnings results after the market closes on Monday, August 11th. Analysts expect Abivax to post earnings of ($0.92) per share and revenue of $1.19 million for the quarter.

Abivax Price Performance

ABVX stock opened at $70.13 on Friday. The firm has a 50 day moving average of $23.93 and a 200 day moving average of $12.52. The company has a current ratio of 1.25, a quick ratio of 1.25 and a debt-to-equity ratio of 1.29. Abivax has a 52 week low of $4.77 and a 52 week high of $75.51.

Institutional Trading of Abivax

Several institutional investors and hedge funds have recently bought and sold shares of the business. Bank of America Corp DE lifted its stake in Abivax by 56.1% during the 4th quarter. Bank of America Corp DE now owns 5,536 shares of the company’s stock valued at $41,000 after acquiring an additional 1,990 shares during the period. Cubist Systematic Strategies LLC lifted its stake in Abivax by 34.3% during the 1st quarter. Cubist Systematic Strategies LLC now owns 10,152 shares of the company’s stock valued at $63,000 after acquiring an additional 2,595 shares during the period. Millennium Management LLC lifted its stake in Abivax by 6.0% during the 1st quarter. Millennium Management LLC now owns 987,414 shares of the company’s stock valued at $6,171,000 after acquiring an additional 56,235 shares during the period. Finally, Woodline Partners LP lifted its stake in Abivax by 319.5% during the 1st quarter. Woodline Partners LP now owns 201,924 shares of the company’s stock valued at $1,262,000 after acquiring an additional 153,788 shares during the period. 47.91% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts recently commented on the stock. Leerink Partners set a $74.00 target price on shares of Abivax and gave the stock an “outperform” rating in a research note on Wednesday, July 23rd. Citigroup reiterated a “market outperform” rating on shares of Abivax in a research note on Friday, July 18th. Lifesci Capital lifted their target price on shares of Abivax from $45.00 to $101.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 23rd. Piper Sandler lifted their target price on shares of Abivax from $70.00 to $112.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 29th. Finally, Guggenheim upped their target price on Abivax from $50.00 to $101.00 and gave the company a “buy” rating in a research report on Wednesday, July 23rd. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $92.33.

About Abivax

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.